RxDoctor Payments DataLook up a doctor →

Donald Farrimond, MD

Family Medicine · Reno, NVNPI 1508811191

Payments from drug & device makers

$8,060in general payments, 2019–2025

Across 522 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$920
  • Esperion Therapeutics, Inc.$790
  • Pfizer$740
  • Astellas Pharma US Inc$460
  • Boehringer Ingelheim$439
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,94199%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,060 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$94,337
Medicare patients
281
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$118,283
OzempicSemaglutide73$66,906
EliquisApixaban76$50,611
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$43,003
XareltoRivaroxaban33$38,487
TrulicityDulaglutide28$37,942
MyrbetriqMirabegron35$25,235
FarxigaDapagliflozin Propanediol17$19,914
Tresiba Flextouch U-100Insulin Degludec12$10,434
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,282
Atorvastatin Calcium474$5,412
Levothyroxine Sodium416$4,938
Omeprazole270$4,778
Rosuvastatin Calcium225$4,139
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$217$156,225124 claims
Novo NordiskOzempic$125$66,90673 claims
PfizerEliquis$740$50,61176 claims
GSKTrelegy Ellipta$920$43,00335 claims
Johnson & JohnsonXarelto$199$38,48733 claims
AstraZenecaFarxiga, Breztri Aerosphere$425$28,19530 claims
Astellas Pharma US IncMyrbetriq$460$25,23535 claims
AbbVieArmour Thyroid$1,658$1,74924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →